First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study

Afchain, Pauline; Chibaudel, Benoist; Lledo, Gérard; Selle, F.; Bengrine-Lefèvre, Léïla; Nguyen, Son; Jf, Paitel; Mineur, Laurent; Artru, Pascal; André, Thierry; Louvet, C.

doi:10.1684/bdc.2009.0871

Cited by 12 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxaliplatin is an effective platinum-based drug used as first line chemotherapy for metastatic colorectal cancer [1]. Moreover it has been used to treat some cisplatin-resistant cancers, including those of the stomach [2], pancreas [3], ovary [4], breast and lung [5]. Oxaliplatin induces DNA crosslinks that cause apoptotic death of dividing cells [6] and reduced tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Multimodal Assessment of Painful Peripheral Neuropathy Induced by Chronic Oxaliplatin-Based Chemotherapy in Mice

et al. 2011

View full text Add to dashboard Cite

BackgroundA major clinical issue affecting 10-40% of cancer patients treated with oxaliplatin is severe peripheral neuropathy with symptoms including cold sensitivity and neuropathic pain. Rat models have been used to describe the pathological features of oxaliplatin-induced peripheral neuropathy; however, they are inadequate for parallel studies of oxaliplatin's antineoplastic activity and neurotoxicity because most cancer models are developed in mice. Thus, we characterized the effects of chronic, bi-weekly administration of oxaliplatin in BALB/c mice. We first studied oxaliplatin's effects on the peripheral nervous system by measuring caudal and digital nerve conduction velocities (NCV) followed by ultrastructural and morphometric analyses of dorsal root ganglia (DRG) and sciatic nerves. To further characterize the model, we examined nocifensive behavior and central nervous system excitability by in vivo electrophysiological recording of spinal dorsal horn (SDH) wide dynamic range neurons in oxaliplatin-treated miceResultsWe found significantly decreased NCV and action potential amplitude after oxaliplatin treatment along with neuronal atrophy and multinucleolated DRG neurons that have eccentric nucleoli. Oxaliplatin also induced significant mechanical allodynia and cold hyperalgesia, starting from the first week of treatment, and a significant increase in the activity of wide dynamic range neurons in the SDH.ConclusionsOur findings demonstrate that chronic treatment with oxaliplatin produces neurotoxic changes in BALB/c mice, confirming that this model is a suitable tool to conduct further mechanistic studies of oxaliplatin-related antineoplastic activity, peripheral neurotoxicity and pain. Further, this model can be used for the preclinical discovery of new neuroprotective and analgesic compounds.

show abstract

Section: Introductionmentioning

confidence: 99%

Multimodal Assessment of Painful Peripheral Neuropathy Induced by Chronic Oxaliplatin-Based Chemotherapy in Mice

et al. 2011

View full text Add to dashboard Cite

show abstract

“…This reflects a pre-FOLFIRINOX era and again highlights the persistent approach to using gemcitabine as a base chemotherapy in first line and 5FU in 2 nd line. Two-drug combinations with gemcitabine have included cisplatin 41 , oxaliplatin 42, 43 , 5FU 44, 45 , docetaxel 41 , irinotecan 38, 44 , or etoposide 46 . Most were conducted prior to publication of corresponding phase III studies showing no benefit to addition of these agents in gemcitabine-based 2 drug regimens.…”

Section: Phase II Clinical Trials In Advanced Pancreatic Cancermentioning

confidence: 99%

Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

Kim¹,

Semrad²,

Bold³

2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction Despite some recent advances in treatment options, pancreatic cancer remains a devastating disease with poor outcomes. In a trend contrary to most malignancies, both incidence and mortality continue to rise due to pancreatic cancer. The majority of patients present with advanced disease and there are no treatment options for this stage that have demonstrated a median survival greater than 1 year. As the penultimate step prior to phase III studies involving hundreds of patients, phase II clinical trials provide an early opportunity to evaluate the efficacy of new treatments that are desperately needed for this disease. Areas Covered This review covers the results of published phase II clinical trials in advanced pancreatic adenocarcinoma published within the past 5 years. The treatment results are framed in the context of the current standards of care and the historic challenge of predicting phase III success from phase II trial results. Expert opinion Promising therapies remain elusive in pancreatic cancer based on recent phase II clinical trial results. Optimization and standardization of clinical trial design in the phase II setting, with consistent incorporation of biomarkers, is needed to more accurately identify promising therapies that warrant phase III evaluation.

show abstract

“…FOLFIRINOX is seldom used in China, as few patients could tolerate this regimen.The safety and efficacy of the Gemox regimen (gemcitabine and oxaliplatin) have been evaluated by numbers of studies as first-line therapy in patients with metastatic or unresectable locally advanced pancreatic cancer 8–12. The objective response rate was 10–30%,13 and the median overall survival was lower than one year 14. Gemox in combination with other therapies, such as erlotinib,15 tomotherapy,16 bevacizumab17 were also be evaluated.…”

Section: Introductionmentioning

confidence: 99%

<p>A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer</p>

Tao

et al. 2019

OTT

View full text Add to dashboard Cite

PurposeThis retrospective study was conducted to evaluate the safety and efficacy of high-intensity focused ultrasound (HIFU) ablation combined with Gemcitabine and Oxaliplatin (Gemox) for the treatment of middle and advanced pancreatic cancer in elderly patients.MethodsForty-seven patients with pancreatic cancer treated with HIFU and Gemox were evaluated for inclusion, and 38 cases were finally included. The primary endpoint was safety. Secondary endpoints included the response rate, the clinical benefit response (CBR), overall survival (OS), progression-free survival (PFS).ResultsAfter combination therapy of HIFU and Gemox, severe complications were rarely reported, and no treatment-related death occurred. The rate of three or four-degree myelosuppression was low, and no obvious impairment of hepatorenal function was observed. Pancreatitis and gastrointestinal injury did not occurred. The disease control rate (DCR) was estimated to be 76.3%, including complete remission (CR), partial remission (PR), stable disease (SD) in 1, 6, 22 cases, respectively. And the objective response rate (ORR) was 18.4%. The clinical benefit rate (CBR) was 68.4%, with the pain significantly relieved (P<0.01). The serum level of CA19-9 showed significant changes after HIFU treatment. The median overall survival (OS) was 12.5 months, with a 6-month and 12-month OS rate of 82.13% and 59.34%, respectively. Stratified analyses did not reveal any significant difference between patients in different stages.ConclusionElderly patients (≥ 60 years old) with pancreatic cancer would experience tolerable toxicity and obtain good clinical benefits from the combination therapy of HIFU ablation and Gemox.

show abstract

First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study

Cited by 12 publications

References 0 publications

Multimodal Assessment of Painful Peripheral Neuropathy Induced by Chronic Oxaliplatin-Based Chemotherapy in Mice

Multimodal Assessment of Painful Peripheral Neuropathy Induced by Chronic Oxaliplatin-Based Chemotherapy in Mice

Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers

<p>A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer</p>

Contact Info

Product

Resources

About